Skip to content

Treatment of Heavy Menstrual Bleeding (periods) with Unani medicine Sharbat Anjbar

Clinical Validation of Unani Pharmacopoeial Formulation Sharbat Anjbar in Kathra al-Tamth (Heavy Menstrual Bleeding)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017823
Enrollment
240
Registered
2019-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

Intervention1: Sharbat Anjbar: 10 ml TDS orally with water for 12 weeks Control Intervention1: nil: nil

Sponsors

Central Council for Research in Unani Medicine CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Non- gravid- non menopausal females with age 25-45years. 2. Patients with Heavy menstrual bleeding as indicated by PBAC score of 100 or more

Exclusion criteria

Exclusion criteria: 1. Patients with irregular and inter-menstrual bleeding. 2. Patients on Anticoagulant or Anti platelet medication. 3. Heavy Menstrual Bleeding with structural abnormality (e.g. fibroid, polyp etc) with symptoms such as inter-menstrual or post-coital bleeding 4. Patients presenting with Heavy Menstrual Bleeding since menarche up to 3 years. 5. Patients with a personal or family history suggesting a coagulation disorder. 6. Patients using OCPs and IUCD. · Patients with illness requiring long term treatment e.g. Hypertension, TB etc. 7. Patients with thyroid disorder. 8. Patients with BMI >30 9. Patients with Heavy Menstrual Bleeding taking Hormone Replacement Therapy. 10. Patients with severe anemia (Hb% less than 7g/dL)

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of Kathra al-Tamth (Heavy Menstrual Bleeding)Timepoint: 12weeks.

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatmen

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026